COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Asciminib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase

Protocol No
HJKC3-0004
Principal Investigator
Ehab Atallah
Phase
II
Summary
The purpose of this study is to determine if taking asciminib may induce continued deep molecular responses in more patients with newly diagnosed CML to make them eligible for treatment discontinuation. We will also investigate whether, for those who do not reach the deepest molecular responses, adding nilotinib might be able to produce a continued MR4.5 response, allowing them the option of treatment discontinuation.
Description
Asciminib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase
Participating Institutions
Froedtert Hospital
Moorland Reserve Health Center
Status
OPEN TO ACCRUAL